Command Palette

Search for a command to run...

Clinical Trials · NCT05689099

A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) Dose

CompletedPhase 1Semaglutide (Approved)
Phase
Phase 1
Recruitment status
Completed
Sponsor
Novo Nordisk A/S
Enrollment
20
Start date
Jan 2023
Locations
1 site, United States
Primary endpoint
AUC0-last,sema 0.5mg: Area under the semaglutide concentration time curve from time 0 until last quantifiable measurement after single dose of subcutaneous semaglutide 0.5 mg
View Semaglutide compound reference